Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 5/20 | 0.73 |
| ▸ | VCAM1 | P19320 | 14/20 | 0.59 |
| ▸ | HPN | P05981 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8235792 | 1.00 | ALOX15 (0.73) | ALOX15VCAM1HPNMAPTSIRT5 | |
| SCHEMBL5575811 | 1.00 | ALOX15 (0.73) | ALOX15VCAM1HPNMAPTSIRT5 | |
| SCHEMBL5576819 | 1.00 | ALOX15 (0.73) | ALOX15VCAM1HPNMAPTSIRT5 | |
| SCHEMBL5574128 | 1.00 | ALOX15 (0.73) | ALOX15VCAM1HPNMAPTSIRT5 | |
| SCHEMBL6890103 | 0.92 | ALOX15 (0.74) | ALOX15VCAM1HPNMAPTSIRT5 | |
| SCHEMBL14586321 | 0.92 | ALOX15 (0.74) | ALOX15VCAM1HPNMAPTSIRT5 | |
| SCHEMBL8234917 | 0.92 | ALOX15 (0.74) | ALOX15VCAM1HPNMAPTSIRT5 | |
| SCHEMBL14417958 | 0.90 | ALOX15 (0.60) | ALOX15VCAM1HPNMAPTSIRT5 | |
| SCHEMBL5576956 | 0.90 | ALOX15 (0.60) | ALOX15VCAM1HPNMAPTSIRT5 | |
| SCHEMBL14417957 | 0.90 | ALOX15 (0.60) | ALOX15VCAM1HPNMAPTSIRT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319349-A1 | Methods for Reducing Platelet Activation and for the Treatment of Thrombotic Events | SCOTT ROBERT A D (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110319349-A1 | Methods for Reducing Platelet Activation and for the Treatment of Thrombotic Events | SCOTT ROBERT A D (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110319349-A1 | Methods for Reducing Platelet Activation and for the Treatment of Thrombotic Events | SCOTT ROBERT A D (US) | 2011-12-29 | — | — | US | disclosed |
| US-7271274-B2 | Phenolic antioxidants for the treatment of disorders including arthritis, asthma and coronary artery disease | AHTEROGENICS, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| US-7271274-B2 | Phenolic antioxidants for the treatment of disorders including arthritis, asthma and coronary artery disease | AHTEROGENICS, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| US-7271274-B2 | Phenolic antioxidants for the treatment of disorders including arthritis, asthma and coronary artery disease | AHTEROGENICS, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| US-20070213303-A1 | Methods for reducing platelet activation and for the treatment of thrombotic events | CRABTREE ACQUISITION CO, LLC | 2007-09-13 | — | — | US | disclosed |
| US-20070213303-A1 | Methods for reducing platelet activation and for the treatment of thrombotic events | CRABTREE ACQUISITION CO, LLC | 2007-09-13 | — | — | US | disclosed |
| WO-2007044726-A2 | METHODS FOR REDUCING PLATELET ACTIVATION AND FOR THE TREATMENT OF THROMBOTIC EVENTS | ATHEROGENICS, INC. (US) | 2007-04-19 | — | — | WO | disclosed |
| US-20060020038-A1 | Phenolic antioxidants for the treatment of disorders including arthritis, asthma and coronary artery disease | CRABTREE ACQUISITION CO, LLC | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319349-A1 | Methods for Reducing Platelet Activation and for the Treatment of Thrombotic Events | PLAT, F2, TFPI | ALOX15 193/4885VCAM1 351/4885HPN 112/4885 |
| US-20070213303-A1 | Methods for reducing platelet activation and for the treatment of thrombotic events | PLAT, F2, TFPI | ALOX15 193/4885VCAM1 351/4885HPN 112/4885 |
| US-20060020038-A1 | Phenolic antioxidants for the treatment of disorders including arthritis, asthma and coronary artery disease | MPO, ALOX15B, ALOX12 | ALOX15 6/4885VCAM1 961/4885HPN 2228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.